| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/27/2007 | CA2647769A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 09/27/2007 | CA2647380A1 Methods for humanizing antibodies and humanized antibodies made thereby |
| 09/27/2007 | CA2647168A1 Methods for increasing the size of animals using needleless delivery constructs |
| 09/27/2007 | CA2647107A1 Anti-tumor cell antigen antibody therapeutics |
| 09/27/2007 | CA2646934A1 Methods for reducing protein aggregation |
| 09/27/2007 | CA2646895A1 Intranasal influenza vaccine based on virosomes |
| 09/27/2007 | CA2646643A1 Methods for preventing and treating amyloidogenic diseases |
| 09/27/2007 | CA2646626A1 Antibody specific for human il-4 for the treatment of cancer |
| 09/27/2007 | CA2646597A1 N-cadherin and ly6 e: targets for cancer diagnosis and therapy |
| 09/27/2007 | CA2646508A1 Stabilized polypeptide compositions |
| 09/27/2007 | CA2646329A1 Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| 09/27/2007 | CA2646004A1 Vaccine for a therapeutic or a prophylactic treatment of myasthenia gravis |
| 09/27/2007 | CA2645891A1 Tumor therapy with an antibody for vascular endothelial groeth factor and an antibody for human epithelial growth factor receptor type 2 |
| 09/27/2007 | CA2645831A1 Anti-tat226 antibodies and immunoconjugates |
| 09/27/2007 | CA2645322A1 Methods of treating lupus using cd4 antibodies |
| 09/27/2007 | CA2644724A1 Methods for preparing complex multivalent immunogenic conjugates |
| 09/27/2007 | CA2644663A1 Agonist antibody to human thrombopoietin receptor |
| 09/27/2007 | CA2638755A1 Methods and compositions for antagonism of rage |
| 09/27/2007 | CA2630344A1 Improved protofibril selective antibodies and the use thereof |
| 09/26/2007 | EP1837399A1 Anticancer agent |
| 09/26/2007 | EP1837342A2 Sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 09/26/2007 | EP1837031A1 Compositions and methods for treating diabetes |
| 09/26/2007 | EP1836294A2 Anti-il-12 antibodies, epitopes, compositions, methods and uses |
| 09/26/2007 | EP1836226A1 Antibodies against il-13 receptor alpha 1 and uses thereof |
| 09/26/2007 | EP1836225A1 Kir-binding agents and methods of use thereof |
| 09/26/2007 | EP1835939A1 Meningococcal conjugate vaccination |
| 09/26/2007 | EP1835937A2 Compositions and methods for treating viral infection |
| 09/26/2007 | EP1835935A2 Compositions and methods for enhanced dendritic cell maturation and function |
| 09/26/2007 | EP1835932A2 Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
| 09/26/2007 | EP1835931A2 Alpha thymosin peptides as cancer vaccine adjuvants |
| 09/26/2007 | EP1835929A2 Anti-kir combination treatments and methods |
| 09/26/2007 | EP1835928A2 Mas related g protein coupled receptors as drug targets |
| 09/26/2007 | EP1835922A1 Combination treatment for multiple sclerosis |
| 09/26/2007 | EP1706485B1 EMPTY CAPSIDS (VLPs(-VP4)) OF THE INFECTIOUS BURSAL DISEASE VIRUS (IBDV), OBTAINMENT PROCESS AND APPLICATIONS |
| 09/26/2007 | EP1411951B1 Enteral compositions for the prevention and/or treatment of sepsis |
| 09/26/2007 | EP1409740B1 Asthma-associated gene |
| 09/26/2007 | EP1391464B1 Anti-cd40 monoclonal antibody |
| 09/26/2007 | EP1263928B1 Identification of antigenic peptides by cytotoxic t lymphocytes activated by dendritic cell hybrids |
| 09/26/2007 | EP1237571B1 Toscana virus nucleoprotein |
| 09/26/2007 | EP1222255B1 Polypeptide fragments comprising c-terminal portion of helicobacter catalase |
| 09/26/2007 | EP1198250B1 Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| 09/26/2007 | EP1198239B1 METHODS EMPLOYING BACTERIAL ParD kis/ParD kid TOXIN-ANTITOXIN SYSTEM FOR KILLING EUKARYOTIC CELLS |
| 09/26/2007 | EP1035865B1 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 09/26/2007 | EP0991663B1 Mycobacterium strain with modified erp gene and vaccine composition containing same |
| 09/26/2007 | EP0937140B1 Antibody molecules which interact specifically with the active site or cleft of a target molecule |
| 09/26/2007 | EP0787191B1 Nucleotide sequences of hiv-1 type (or subtype) o retrovirus antigens |
| 09/26/2007 | CN101044247A Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 09/26/2007 | CN101044242A Tumor specific antibody |
| 09/26/2007 | CN101044165A Irta-4 antibodies and their uses |
| 09/26/2007 | CN101044160A Methods of diagnosis and treatment of m. tuberculosis infection and reagents therefor |
| 09/26/2007 | CN101043904A Nutritional composition comprising indigestible oligosaccharides |
| 09/26/2007 | CN101043903A Methods and compositions for combinatoral-based production of multivalent recombinant antigens |
| 09/26/2007 | CN101043902A Vaccine composition against hepatitis c virus |
| 09/26/2007 | CN101043901A Method for preventing and treating alzheimer's disease |
| 09/26/2007 | CN101041820A Macrophagocyte transfer inhibition factor monoclonal antibody and method for making same |
| 09/26/2007 | CN101041079A Novel colloid synthetic vectors for gene therapy |
| 09/26/2007 | CN101041077A Biphase emulsification adjuvant and the technique for preparing the same |
| 09/26/2007 | CN101041071A Interacted proteins of APC10 and the function for adjusting the cell period thereof |
| 09/26/2007 | CN100339396C Multi-helix protein for inhibiting membrane virus infection, its coding gene and use |
| 09/26/2007 | CN100339395C E type hepatitis virus monoclonal antibody or its conjugated active fragment and use thereof |
| 09/26/2007 | CN100339394C 组织特异性表达 Tissue-specific expression |
| 09/26/2007 | CN100339391C Coronavirus (SARS-CoV)B-cell antigen determinate cluster with extensive cross immune activity |
| 09/26/2007 | CN100339386C Animal composite immune globulin production method |
| 09/26/2007 | CN100339132C Antithrombotic agents |
| 09/26/2007 | CN100339131C IHNV G protein for immune stimulation |
| 09/26/2007 | CN100339130C 疫苗 Vaccine |
| 09/26/2007 | CN100339066C Stable injecta composition and method |
| 09/25/2007 | US7273932 Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use |
| 09/25/2007 | US7273930 Immunization of dairy cattle with GapC protein against Streptococcus infection |
| 09/25/2007 | US7273928 Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin |
| 09/25/2007 | US7273925 Methods and products for regulating lectin complement pathway associated complement activation |
| 09/25/2007 | US7273924 Antibodies to the ED-B domain of fibronectin, their construction and uses |
| 09/25/2007 | US7273752 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, |
| 09/25/2007 | US7273744 Heparanase-like polypeptides |
| 09/25/2007 | US7273709 Detection of sarcocystis neurona |
| 09/25/2007 | US7273695 HIV immunoassays using synthetic envelope polypeptides |
| 09/25/2007 | US7273617 Vaccines |
| 09/25/2007 | US7273616 Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof |
| 09/25/2007 | US7273614 Inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells. |
| 09/25/2007 | US7273613 Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders |
| 09/25/2007 | US7273612 Soluble inhibitors of vascular endothelial growth factor and use thereof |
| 09/25/2007 | US7273611 Proteinase K resistant surface protein of neisseria meningitidis |
| 09/25/2007 | US7273610 Endotheliase-2 ligands |
| 09/25/2007 | US7273609 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| 09/25/2007 | US7273608 Humanized anti-CEA T84.66 antibody and uses thereof |
| 09/25/2007 | US7273605 Containing a priming and boosting composition, each with a non-replicating viral vector, with at least one of them being derived from a fowlpox virus; malaria, tuberculosis |
| 09/25/2007 | US7273602 Immunotherapy for humans |
| 09/25/2007 | CA2503774C Improvements in virus production |
| 09/25/2007 | CA2294649C Bovine adenovirus type 3 genome |
| 09/25/2007 | CA2266486C Rotavirus vaccine formulations |
| 09/25/2007 | CA2222515C High moisture nutrient formulation for poultry and other animals |
| 09/25/2007 | CA2173592C Stem cell proliferation factor |
| 09/25/2007 | CA2132868C Method of using antibodies against human chorionic gonadotropin-related determinants to lyse, measure and enrich malignant cells |
| 09/25/2007 | CA2128109C Improvements in or relating to malaria vaccine |
| 09/25/2007 | CA2112701C Proteins s polypeptides and uses thereof |
| 09/20/2007 | WO2007106811A2 Method and composition for treatment of renal disease with antibodies and their equivalents |
| 09/20/2007 | WO2007106617A2 Method of treatment and prophylaxis of diseases related to amyloid deposition using igm |
| 09/20/2007 | WO2007106585A1 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| 09/20/2007 | WO2007106576A2 Methods and materials for immunization against cancer |
| 09/20/2007 | WO2007106476A2 Compositions and methods for enhancing the immunogenicity of antigens |